The date the provider was assigned a unique identifier (assigned an NPI). The provider other organization name codes are:
#Songbird therapy code
The code identifying the type of other name. The other organization name is the alternative last name by which the provider is or has been known (if an individual) or other name by which the organization provider is or has been known. These components are often separately licensed or certified by States and may exist at physical locations other than that of the hospital of which they are a component. Hospital components include outpatient departments, surgical centers, psychiatric units, and laboratories. Subparts are the components and separate physical locations of organization health care providers. 2 = Non-person: entity other than an individual human being that furnishes health care (Examples: hospital, SNF, hospital subunit, pharmacy, or HMO).1 = Person: individual human being who furnishes health care.The entity type code describes the type of health care provider that is being assigned an NPI. Songbird Therapy is registered as an entity type code: 2. This address may contain the same information as the provider location address. The mailing address of the provider being identified. This address cannot include a Post Office box. For providers with more than one physical location, this is the primary location. The location address of the provider being identified. The NPI is 10-position all-numeric identification number assigned by the NPPES to uniquely identify a health care provider. Frias and Sandrine LecourĪbstract: High density lipoproteins have a well-established, negative correlation with risk of cardiovascular disease.What is the National Provider Indentifier (NPI)? Title:Lipid-Induced Modulation of Protective Signalling Pathways in Cardiovascular Disease: The Role of High Density LipoproteinsĪuthor(s): Richard W. Keywords: Apolipoprotein AI cardiomyocyte endothelium HDL ischemia-reperfusion injury sphingosine-1-phosphate
Such studies have already been initiated, as will be discussed below. In this respect theĪbility to synthesise artificial high density lipoproteins with functional properties of the native lipoprotein complex is a Logical extension is to consider the high density lipoprotein complex itself as a potential therapeutic. These studies may identify new avenues that can be explored as potential targets to treat cardiovascular disease. Advances in this area will be discussed in the following Notably be defining the signalling pathways that are involved. On-going studies are investigating the magnitude of the influence of the lipoprotein on cell function, The lipoprotein influences theįunctioning of endothelial cells and cardiomyocytes in a manner suggesting a protective effect under conditions of More recent studies suggest that high density lipoproteins have a more widespread impact onĬardiovascular pathophysiology, beyond its involvement in cholesterol metabolism. There is currently particular interest in trying to exploit this relationship by raising serum high density lipoproteinĬholesterol to lower risk. High density lipoproteins have a well-established, negative correlation with risk of cardiovascular disease.
0 kommentar(er)
